The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ECOG 8141: A prospective phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma.
 
Jean H. Hoffman-Censits
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Vitaly Margulis
Honoraria - Astellas Pharma; Bayer; ferring; Johnson & Johnson
Speakers' Bureau - Astellas Pharma; Bayer; Ferring; Johnson & Johnson
 
Noah M. Hahn
Honoraria - D3 Oncology Solutions
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Medivation; Merck; Oncogenex
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst)
 
Edouard John Trabulsi
No Relationships to Disclose
 
Allison Beaver
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Acceleron Pharma (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)